CombiMatrix has appointed Colin Collins to the scientific advisory board of its subsidiary, CombiMatrix Molecular Diagnostics. Collins is associate professor of urology at the Cancer Research Institute and the department of molecular medicine at the University of California, San Francisco.
Collins’ research has led to the identification of genetic markers that have been used to risk-stratify cancer patients. He also invented a method of analyzing the structure of tumor genomes called end sequence profiling.
BioTrove has appointed Derek Potter to be director of European business operations, a position based in London. Potter formerly was European sales manager for Applied Biosystems, and he was involved in establishing Fluidigm’s European operations.